The Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship at Washington University in St. Louis recently announced six teams were selected for funding to prepare their projects for commercialization through the spring 2020 LEAP Gap Fund cycle.
The LEAP Gap Fund is open to any person or team with potential or existing university intellectual property. Through the program, teams receive mentorship from experts in their fields, and they work with the Skandalaris Center and partners to create clear development and commercialization plans.
Six teams were selected for funding to ready their projects for commercialization.
COMMERCIALIZATION OF SCBETA TECHNOLOGIES
Manufacturing and distribution of research-grade SC-Beta cells.
- Leonardo Velazco-Cruz – PhD Candidate, DBBS Graduate Research Assistant
- Kristina Maxwell – PhD Candidate
- Punn Augsornworawat– PhD Candidate
- Jeffrey Millman, PhD – Assistant Professor of Medicine and Biomedical Engineering, School of Medicine
- Nathaniel Hogrebe, PhD – Postdoctoral Research Fellow, School of Medicine…
…SYMPEL (SYMPATHETIC ELECTRODE SYSTEM): A SIMPLE NEUROMODULATION SOLUTION TO ADDRESS COMPLICATED DISEASES
A patent-pending, platform neuromodulation electrode system designed to be easily placed in a minimally invasive manner near the sympathetic chain located on the sides of the spine.
- Eric Leuthardt, MD, FNAI – Professor of Neurological Surgery, School of Medicine
- Dan Moran, PhD – Professor, Biomedical Engineering, McKelvey School of Engineering…
…TARGETING CA2+-PERMEABLE AMPA RECEPTORS FOR INNER EAR THERAPY
The first-ever drug for the prevention of hearing loss and/or tinnitus.
- Mark Rutherford, PhD – Assistant Professor, Otolaryngology, School of Medicine
- Steven Green, PhD – Professor of Biological Sciences and Otolaryngology, The University of Iowa
- Roland Dolle, PhD – Chemistry Director, Center for Drug Discovery, School of Medicine